Skip to main content
Experimental and Therapeutic Medicine logoLink to Experimental and Therapeutic Medicine
. 2018 Mar 6;15(5):4344–4348. doi: 10.3892/etm.2018.5924

Identification of modules of hepatic encephalopathy based on protein-protein network and gene expression data

Hao Wu 1, Miao Liu 1, Jiajun Zhuang 2,
PMCID: PMC5962850  PMID: 29849776

Abstract

Hepatic encephalopathy (HE) is regarded as a complication of liver cirrhosis, and 50–75% of patients who have been diagnosed with cirrhosis have HE syndrome. The aim of this study was to identify genes and pathways associated with HE alcoholics. Human protein-protein interactions were downloaded from the STRING database. Gene expression data were downloaded from EMBL-EBI. Combined score and Pearson's correlation coefficient were calculated to construct differential co-expression networks. Graph-theoretical measure was used to calculate the module connectivity dynamic score of multiple differential modules. In total, 11,134 genes were obtained after mapping between probes and genes. Then, 501,736 pairs and 16,496 genes were obtained to form background protein-protein interaction networks, 1,435 edges and 460 nodes were obtained constituting differential co-expression networks. Twenty-three seed genes and 10 significantly differential modules were identified. Four significantly differential modules which had larger connectivity alternation were observed. The identified seed genes and significantly differential modules offer novel understanding and molecular targets for the treatment of HE alcoholics.

Keywords: hepatic encephalopathy, multiple differential module, protein-protein interaction, gene expression profiling, central nervous system

Introduction

Hepatic encephalopathy (HE) is a complication of liver cirrhosis (1), and 50–75% of patients who have been diagnosed with cirrhosis have the HE syndrome (2,3). The HE also has other types classified according to the standard constituted at the World Congress of Gastroenterology in 1998, including encephalopathy associated with acute liver disease and encephalopathy without liver disease (4). It is reported that the damage of astrocytes triggers disturbance of neurotransmission and induces development of HE (5). Astrocytes play an important role in the central nervous system (CNS) and constitute about a third of brain cortical volume (6). Astrocytes act as the main regulators in neurotransmitters, such as transition of amino acids (7). Glutamine synthase, which maintains an ammonia balance in the human body, converts glutamate and ammonia into glutamine. Glutamine synthase is mainly contained in astrocytes (8).

Ammonia is known as a main cause of HE. It is reported that most of HE is associated with high a concentration of ammonia (9). Ammonia is mainly produced in the gut and synthesized by bacteria. High levels of ammonia disturb the neural system function and neurotransmission. Up to now, the main treatment for HE focuses on reducing the production and concentration of ammonia (10). It is reported that sodium benzoate and sodium phenylacetate are used as ammonia cleaners in patients who are diagnosed with hyperammonemia or urea cycle disorder (11). Glycerol phenylbutyrate is used to treat HE through the regulation of ammonia metabolism. Glycerol phenylbutyrate is a pro-drug of phenylacetate and decomposes nitrogen to urinary phenylacetylglutamine (12). Polyethylene glycol 3350 is used to clean the intestine and has proven to be a more effective therapy than lactulose (β-1, 4-galactosido-fructose) (13). Bass et al reported rifaximin significantly decreased the risk of HE compared with placebo and approximately 90% of patients were treated with lactulose (14). Lactulose, a disaccharide, cannot be digested by human intestinal disaccharidases (15). Lactulose is digested into small molecular organic acids, such as acetic acid and lactic acid. The osmotic effect produced by these acids induces fermentative diarrhoea (16). Lactulose was first reported to be used as treatment for HE in 1966 (17). Rahimi et al reported that lactulose caused more acute electrolyte imbalance and loss than PEG (18). Besides that, hepatic encephalopathy occurs as a complication of alcoholic liver disease mainly found in the most advanced stage (19). And while hepatic encephalopathy occurs in earlier stages, it is usually a consequence of excessive alcohol consumption before the onset of encephalopathy.

In addition, substantial molecular research is associated with HE. Protein-protein interactions (PPIs) processed by bioinformatic algorithms have been used to search for biomarkers and biological pathways in various types of cancer, such as breast cancer (20), lung cancer (21,22), colon cancer (23), ovarian cancer (24) and glioma (25).

In the present study, we downloaded all human PPI networks and gene expression data associated with HE alcoholics. Differential co-expression networks (DCNs), which comprise 1435 edges and 460 nodes were constructed based on PPI networks and gene expression data. Twenty-three seed genes and 13 multiple differential modules (M-DMs) were identified. Ten differential modules were found when P-values were <0.05. Four differential modules had major connectivity alternation using the graph-theoretical measure method.

Materials and methods

Gene expression data

Gene expression data associated with HE alcoholics E-GEOD-53808 were downloaded from the European Molecular Biology Laboratory at European Bioinformatics Institute (EMBL-EBI). The data contained 9 control samples, 15 non-HE alcoholic samples and 8 HE alcoholic samples.

PPI networks

All human PPI networks were downloaded from the String database. There were 787,896 pairs of PPI networks and 16,730 genes. PPI network pairs were selected when the combined scores were >0.2. Then, 501,736 pairs and 16,496 genes were obtained, and these genes and networks formed background PPI networks. Expression profiling was chosen if they contained genes belonging to background PPI networks. The new expression profiling data contained 9,608 genes.

Construction of DCNs

The PPI networks were selected from background PPI networks if they contained genes belonging to the new expression profiling. The Pearson's correlation coefficients of HE and non-HE alcoholics were calculated respectively. Edges were observed when absolute values of Pearson's correlation coefficient were greater than δ (δ=0.9). P-values of genes in the DCNs of two groups were calculated using one-side t-test algorithm. Weight value between gene i and gene j was calculated as:

wi,j{(logpi+logpj)1/2(2*maxlV|logpl|)1/2,ifcor(i,j)δ,0,ifcor(i,j)<δ,

V denotes a node set of DCN.

Identification of M-DMs

M-DMs were identified from DCNs. The process comprises of three steps: ⅰ) seed prioritization, ⅱ) module search and ⅲ) refinement of M-modules. Importance value (score value) of each gene in DCNs was calculated as:

g(i)=jNk(i)Aijkg(j)

Each network had an adjacent matrix. Nk(i) represents adjacent nodes of gene i in Gk network, A'k represents adjacent matrix which was weighted by normalized degree; g(i) equals z-score. The z-score of each gene in the DCNs was averaged and ranked. One seed gene was regarded as differential module C. Then, gene u, which was adjacent to gene v, was joined into module C to form module C'. The entropy of the two modules was calculated as:

Hk(Ci)=piklogpik(1pik)log(1pik)pik=Lk(i)Lk(i)+Lk(i)Lk(i)=ji,jCaij

Lk(i) denotes total weight between gene i and other nodes in modules C. Lk(i) represents weight between gene i and other nodes in modules C.

Hk(C)=iCH(Ci)H(C)=k=1MHk(C)|C|

The candidate modules which had <4 nodes were eliminated. Two modules were merged into one module if the overlapped degree of two modules was >0.05. In total, 13 modules were identified.

Significant statistical test of candidate modules

One thousand, four hundred and thirty-five edges were selected from 178,888 edges and regarded as the random network. Module search processing was done following the above methods. Construction of random networks was repeated 100 times and 3,696 modules were generated. The P-value of the candidate module was calculated as the probability of the module, which has the observed score or smaller by chance. The Benjamini-Hochberg method (26) was used to correct the P-value. Ten modules were identified as significantly differential modules as P-values were ≤0.05.

Quantification of M-DMs connectivity and significance analysis

Graph-theoretical measure method was used to calculate module connectivity dynamic score (MCDS). MCDS between two adjacent modules was calculated as:

MCDS=ΔAi,i+1C=AiCAi+1C2/|C|

C denotes one differential module, AiC presents adjacent matrix of C. The total MCDS of differential module C equals the average of MCDS of all adjacent modules.

τ(AC)=i=1M1ΔAi,i+1C/(M1)

Differential modules were regarded as significantly differential modules of connectivity alternation at P-value <0.05.

Results

Gene expression data and PPI network processing

Gene expression data E-GEOD-53808 were downloaded from the EMBL-EBI database, and 11,134 genes were obtained following mapping between probes and genes. The human PPI networks were downloaded from the STRING database. Networks comprised of 787,896 pairs of PPI networks and 16,730 genes.

PPI network pairs were selected if their combined scores were >0.2. Pairs (50,1736) and 16,496 genes were obtained to form background PPI networks. The new expression profiling data identified contained 9,608 genes.

Identification of DCNs

Interaction pairs (178,888) which contained genes of new expression profiling were identified. These pairs were selected from background PPIs. The edges were selected if absolute values of Pearson's correlation coefficient were >0.9. One thousand, four hundred and thirty-five edges and 460 nodes were obtained and constituted DCNs. Two DCNs, constituting the non-HE alcoholics and HE alcoholics groups, were identified. Two DCNs had the same node sets and different edge sets.

Identification of M-DMs

The important value (z-score) of each gene was calculated. The z-score of each gene in all the DCNs were averaged and ranked. Top 5% genes were selected as seed genes and 23 seed genes were identified (Table I).

Table I.

Twenty-three seed genes identified by z-score.

Name z-score 1 z-score 2 Average
PSMA3 86.5335583 122.6082221 104.57089
RPS13 34.8732349 120.1981589 77.535697
RPL8 25.1907276 97.03482872 61.112778
PSMA2 57.812847 64.10648625 60.959667
AHSA1 81.0358135 37.6419885 59.338901
RPS5 22.1380737 96.04627227 59.092173
EEF1B2 29.0671882 88.5651997 58.816194
RPS12 20.7253557 95.23469314 57.980024
RPL35 26.199604 89.41832806 57.808966
PSMC2 58.4824325 50.02097225 54.251702
ATP5B 31.4457881 76.47658876 53.961188
SPCS1 37.2801529 69.5430352 53.411594
NDUFAB1 26.0584344 79.74001391 52.899224
EIF1B 43.2034053 62.06634957 52.634877
NDUFB3 25.9831661 78.69291867 52.338042
NDUFV2 33.9425327 69.17172639 51.55713
RPL18A 20.9168676 81.97652628 51.446697
RPL19 25.2334709 76.47090293 50.852187
GAPDH 23.1407005 76.70369969 49.9222
PSMA5 52.2804348 47.28292135 49.781678
RPL18 23.4177997 73.9560672 48.686933
SYP 25.0252229 71.74102033 48.383122
RPS16 23.0946453 73.32578699 48.210216

Modules were searched based on each gene. Entropy of two modules and change of entropy were calculated. Candidate modules were eliminated if nodes were <5. Two modules were merged into one module if the overlap degree was ≥0.5. Finally, 13 modules were identified.

Significant test of candidate modules

One thousand, four hundred and thirty-five edges were chosen from 178,888 edges randomly to constitute one random network. The random networks were constructed 100 times, and gene rated 3,696 modules. After P-values were corrected by the Benjamini-Hochberg algorithm, 10 significant differential modules were identified.

Quantification of connectivity dynamics of M-DMs and statistical significant test

Graph-theoretical measure algorithm was used to calculate MCDS. MCDS between two modules and total MCDS were calculated. Four significant differential modules, which had larger connectivity alternation were found (P<0.05) (Fig. 1). Module 1 contains 80 nodes and 478 edges; module 2 comprises 36 nodes and 119 edges; module 3 contains 42 nodes and 145 edges; module 4 comprises of 25 nodes and 64 edges.

Figure 1.

Figure 1.

Four significant differential modules with larger connectivity alternation: (A) 80 nodes and 478 edges; (B) 36 nodes and 119 edges; (C) 42 nodes and 145 edges and (C) 25 nodes and 64 edges.

Discussion

Alcohol damage on hepatic cells impairs enzyme activities and detoxification of liver. In addition, impairment of hepatic cells disturb brain functions (27). Hepatic encephalopathy (HE) is a serious complication of alcoholic-associated hepatic disease (19). HE has various clinical syndromes, such as nausea, malaise, asterixis and coma (28,29).

In the present study, we obtained all the PPI networks and gene expression data from international databases. We identified 23 seed genes and 10 significant differential modules associated with HE alcoholics. Four differential modules, which had lager connectivity alternations, were obtained by calculating the module connectivity dynamic score of M-DMs.

The 23 genes identified in this study included PSMA3, RPS13, RPL8, PSMA2, AHSA1, RPS5, EEF1B2, PSMC2, ATP5B and NDUFV2. PSMA3 is one subunit of 20S proteasome and interacted with ROA1, PCBP2 and IREB2. These proteins function in RNA processing, such as splicing (30). PSMA3 (rs2348071) GG homozygote is related to children with asthma, and children with GG homozygotes are susceptible to disease in Taiwan (31). The potential function of PSMA3 was analyzed in HE alcoholics.

Proteasome 26S subunit ATPase 2 (PSMC2) is an important component of 26S proteasome. The complex processes substrates into 20S pivotal component (32). PSMC2 expression level is increased in osteosarcoma and silencing of PSMC2 suppresses cell growth and migration (33). In a further study, we will investigate the function of PSMC2. The 26S proteasome may play a role in HE alcoholics.

ATP5b is one subunit of ATP synthase complex. α2/δ1 interacts with ATP5b and constitute a complex in intracellular membrane. The complex is capable of regulating calcium metabolism and promotes a decreasing rate of calcium transients (34). The ATP5b expression level was markedly increased in colorectal tumor tissues compared with normal tissues, but the expression level of ATP5b has no association with tumor location (35). ATP synthase complex can generate energy and the energy supply may affect the treatment of HE alcoholics.

Activator of 90KD heat shock protein ATPase homolog 1 (AHSA1) is an important factor that can activate ATPase of HSP90, which also is a chaperone of HSP90 (36). In osteosarcoma, AHSA1 promotes cell proliferation, migration, and invasion by regulating Wnt/β (37). In a further study, we will clone the AHSA1 sequence, and investigate its effect on cell proliferation and treatment of HE alcoholics.

In eukaryotic cells, Rps5/uS7 is a subunit of 40S protein complex, which plays an important role in recognition of initiated codon. Substitution in C-terminal residues and β-strand of Rps5 subunit reduces initiation rate and recognition accuracy (38). There is no study of Rsp5 on HE alcoholics.

It is reported that EEFIB has four loci, including EEF1B1, EEF1B2, EEF1B3 and EEF1B4. Three of them are functional (39). EEF1B2 is mapped to chromosome 2 by PCR method (40). EEF1B2 is related with retrotransposition function and capable of transcriptional activity (41).

NADH dehydrogenase ubiquinone flavoprotein 2 (NDUFV2) encodes one 24 kDa component of NADH-ubiquinone oxidoreductase complex and is involved in electron transportion (42). NDUFV2 is involved in neuronal mobility and psychiatric dysfunction (43). The 3542G>A polymorphism, which is located at the promoter region of NDUFV2, is associated with bipolar disorder (44). Therefore, we suggested that NDUFV2 may play an important role in HE progression.

In conclusion, we identified 23 seed genes and 10 significantly differential modules associated with HE alcoholics. Four modules were identified as they had relatively larger connectivity alternations. The newly identified seed genes and modules offer understanding of the potential mechanisms and biomarkers for the therapeutic target of HE alcoholics.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

HW conceived and designed the study and wrote the manuscript; ML performed the data analyses; JZ contributed to the conception of the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–721. doi: 10.1053/jhep.2002.31250. [DOI] [PubMed] [Google Scholar]
  • 2.Cichoż-Lach H, Michalak A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. World J Gastroenterol. 2013;19:26–34. doi: 10.3748/wjg.v19.i1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Patel D, McPhail MJ, Cobbold JF, Taylor-Robinson SD. Hepatic encephalopathy. Br J Hosp Med (Lond) 2012;73:79–85. doi: 10.12968/hmed.2012.73.2.79. [DOI] [PubMed] [Google Scholar]
  • 4.Atluri DK, Prakash R, Mullen KD. Pathogenesis, diagnosis, and treatment of hepatic encephalopathy. J Clin Exp Hepatol. 2011;1:77–86. doi: 10.1016/S0973-6883(11)60126-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: A clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol. 2000;32:1035–1038. doi: 10.1016/S0168-8278(00)80110-5. [DOI] [PubMed] [Google Scholar]
  • 6.Wilson JX. Antioxidant defense of the brain: A role for astrocytes. Can J Physiol Pharmacol. 1997;75:1149–1163. doi: 10.1139/y97-146. [DOI] [PubMed] [Google Scholar]
  • 7.Henn FA, Hamberger A. Glial cell function: Uptake of transmitter substances. Proc Natl Acad Sci USA. 1971;68:2686–2690. doi: 10.1073/pnas.68.11.2686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Torgner I, Kvamme E. Synthesis of transmitter glutamate and the glial-neuron interrelationship. Mol Chem Neuropathol. 1990;12:11–17. doi: 10.1007/BF03160053. [DOI] [PubMed] [Google Scholar]
  • 9.Adams RD, Foley JM. The neurological disorder associated with liver disease. Res Publ Assoc Res Nerv Ment Dis. 1953;32:198–237. [PubMed] [Google Scholar]
  • 10.Tapper EB, Jiang ZG, Patwardhan VR. Refining the ammonia hypothesis: A physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clin Proc. 2015;90:646–658. doi: 10.1016/j.mayocp.2015.03.003. [DOI] [PubMed] [Google Scholar]
  • 11.Ghabril M, Zupanets IA, Vierling J, Mantry P, Rockey D, Wolf D, O'Shea R, Dickinson K, Gillaspy H, Norris C, et al. Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: A pilot study of safety and effect on venous ammonia concentration. Clin Pharmacol Drug Dev. 2013;2:278–284. doi: 10.1002/cpdd.18. [DOI] [PubMed] [Google Scholar]
  • 12.Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, Marier JF, Beliveau M, Mauney J, Dickinson K. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: Safety, pharmacokinetics and ammonia control. Mol Genet Metab. 2010;100:221–228. doi: 10.1016/j.ymgme.2010.03.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rahimi RS, Rockey DC. Hepatic encephalopathy: Pharmacological therapies targeting ammonia. Semin Liver Dis. 2016;36:48–55. doi: 10.1055/s-0036-1571298. [DOI] [PubMed] [Google Scholar]
  • 14.Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–1081. doi: 10.1056/NEJMoa0907893. [DOI] [PubMed] [Google Scholar]
  • 15.Mozdziak PE, Pophal S, Borwornpinyo S, Petitte JN. Transgenic chickens expressing beta-galactosidase hydrolyze lactose in the intestine. J Nutr. 2003;133:3076–3079. doi: 10.1093/jn/133.10.3076. [DOI] [PubMed] [Google Scholar]
  • 16.Haemmerli UP, Kistler H, Ammann R, Marthaler T, Semenza G, Auricchio S, Prader A. Acquired milk intolerance in the adult caused by lactose malabsorption due to a selective deficiency of intestinal lactase activity. Am J Med. 1965;38:7–30. doi: 10.1016/0002-9343(65)90156-7. [DOI] [PubMed] [Google Scholar]
  • 17.Bircher J, Müller J, Guggenheim P, Haemmerli UP. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet. 1966;1:890–892. doi: 10.1016/s0140-6736(66)91573-x. [DOI] [PubMed] [Google Scholar]
  • 18.Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350 - electrolyte solution for treatment of overt hepatic encephalopathy: The HELP randomized clinical trial. JAMA Intern Med. 2014;174:1727–1733. doi: 10.1001/jamainternmed.2014.4746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Piechota M. Hepatic encephalopathy in the course of alcoholic liver disease - treatment options in the intensive care unit. Anaesthesiol Intensive Ther. 2014;46:34–36. doi: 10.5603/AIT.2014.0007. [DOI] [PubMed] [Google Scholar]
  • 20.Zhang F, Ren C, Zhao H, Yang L, Su F, Zhou MM, Han J, Sobie EA, Walsh MJ. Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data. Oncotarget. 2016;7:71620–71634. doi: 10.18632/oncotarget.12287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wu CH, Hsu CL, Lu PC, Lin WC, Juan HF, Huang HC. Identification of lncRNA functions in lung cancer based on associated protein-protein interaction modules. Sci Rep. 2016;6:35939. doi: 10.1038/srep35939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chen L, Huang T, Zhang YH, Jiang Y, Zheng M, Cai YD. Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach. Sci Rep. 2016;6:29849. doi: 10.1038/srep29849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hollander D, Donyo M, Atias N, Mekahel K, Melamed Z, Yannai S, Lev-Maor G, Shilo A, Schwartz S, Barshack I, et al. A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. Genome Res. 2016;26:541–553. doi: 10.1101/gr.193169.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zhang D, Chen P, Zheng CH, Xia J. Identification of ovarian cancer subtype-specific network modules and candidate drivers through an integrative genomics approach. Oncotarget. 2016;7:4298–4309. doi: 10.18632/oncotarget.6774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Azevedo H, Moreira-Filho CA. Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma. Sci Rep. 2015;5:16830. doi: 10.1038/srep16830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Feser WJ, Fingerlin TE, Strand MJ, Glueck DH. Calculating average power for the Benjamini-Hochberg procedure. J Stat Theory Appl. 2009;8:325–352. [PMC free article] [PubMed] [Google Scholar]
  • 27.Butterworth RF. Hepatic encephalopathy - a serious complication of alcoholic liver disease. Alcohol Res Health. 2003;27:143–145. [PMC free article] [PubMed] [Google Scholar]
  • 28.Córdoba J, García-Martinez R, Simón-Talero M. Hyponatremic and hepatic encephalopathies: Similarities, differences and coexistence. Metab Brain Dis. 2010;25:73–80. doi: 10.1007/s11011-010-9172-3. [DOI] [PubMed] [Google Scholar]
  • 29.Ortiz M, Jacas C, Córdoba J. Minimal hepatic encephalopathy: Diagnosis, clinical significance and recommendations. J Hepatol. 2005;42(Suppl):S45–S53. doi: 10.1016/j.jhep.2004.11.028. [DOI] [PubMed] [Google Scholar]
  • 30.Fedorova OA, Moiseeva TN, Nikiforov AA, Tsimokha AS, Livinskaya VA, Hodson M, Bottrill A, Evteeva IN, Ermolayeva JB, Kuznetzova IM, et al. Proteomic analysis of the 20S proteasome (PSMA3)-interacting proteins reveals a functional link between the proteasome and mRNA metabolism. Biochem Biophys Res Commun. 2011;416:258–265. doi: 10.1016/j.bbrc.2011.10.126. [DOI] [PubMed] [Google Scholar]
  • 31.Sjakste T, Paramonova N, Rumba-Rozenfelde I, Trapina I, Sugoka O, Sjakste N. Juvenile idiopathic arthritis subtype- and sex-specific associations with genetic variants in the PSMA6/PSMC6/PSMA3 gene cluster. Pediatr Neonatol. 2014;55:393–403. doi: 10.1016/j.pedneo.2014.01.007. [DOI] [PubMed] [Google Scholar]
  • 32.Smith DM, Fraga H, Reis C, Kafri G, Goldberg AL. ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle. Cell. 2011;144:526–538. doi: 10.1016/j.cell.2011.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Song M, Wang Y, Zhang Z, Wang S. PSMC2 is up-regulated in osteosarcoma and regulates osteosarcoma cell proliferation, apoptosis and migration. Oncotarget. 2017;8:933–953. doi: 10.18632/oncotarget.13511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.García J. The calcium channel α2/δ1 subunit interacts with ATP5b in the plasma membrane of developing muscle cells. Am J Physiol Cell Physiol. 2011;301:C44–C52. doi: 10.1152/ajpcell.00405.2010. [DOI] [PubMed] [Google Scholar]
  • 35.Geyik E, Igci YZ, Pala E, Suner A, Borazan E, Bozgeyik I, Bayraktar E, Bayraktar R, Ergun S, Cakmak EA, et al. Investigation of the association between ATP2B4 and ATP5B genes with colorectal cancer. Gene. 2014;540:178–182. doi: 10.1016/j.gene.2014.02.050. [DOI] [PubMed] [Google Scholar]
  • 36.Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, Millson SH, Clarke PA, Naaby-Hansen S, Stein R, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell. 2002;10:1307–1318. doi: 10.1016/S1097-2765(02)00785-2. [DOI] [PubMed] [Google Scholar]
  • 37.Shao J, Wang L, Zhong C, Qi R, Li Y. AHSA1 regulates proliferation, apoptosis, migration, and invasion of osteosarcoma. Biomed Pharmacother. 2016;77:45–51. doi: 10.1016/j.biopha.2015.11.008. [DOI] [PubMed] [Google Scholar]
  • 38.Visweswaraiah J, Pittman Y, Dever TE, Hinnebusch AG. The β-hairpin of 40S exit channel protein Rps5/uS7 promotes efficient and accurate translation initiation in vivo. eLife. 2015;4:e07939. doi: 10.7554/eLife.07939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pizzuti A, Gennarelli M, Novelli G, Colosimo A, Lo Cicero S, Caskey CT, Dallapiccola B. Human elongation factor EF-1 beta: Cloning and characterization of the EF1 beta 5a gene and assignment of EF-1 beta isoforms to chromosomes 2,5,15 and X. Biochem Biophys Res Commun. 1993;197:154–162. doi: 10.1006/bbrc.1993.2454. [DOI] [PubMed] [Google Scholar]
  • 40.Sanders J, Maassen JA, Amons R, Möller W. Nucleotide sequence of human elongation factor-1 beta cDNA. Nucleic Acids Res. 1991;19:4551. doi: 10.1093/nar/19.16.4551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Chambers DM, Rouleau GA, Abbott CM. Comparative genomic analysis of genes encoding translation elongation factor 1B(alpha) in human and mouse shows EEF1B1 to be a recent retrotransposition event. Genomics. 2001;77:145–148. doi: 10.1006/geno.2001.6626. [DOI] [PubMed] [Google Scholar]
  • 42.de Coo R, Buddiger P, Smeets H, van Kessel Geurts A, Morgan-Hughes J, Weghuis DO, Overhauser J, van Oost B. Molecular cloning and characterization of the active human mitochondrial NADH:ubiquinone oxidoreductase 24-kDa gene (NDUFV2) and its pseudogene. Genomics. 1995;26:461–466. doi: 10.1016/0888-7543(95)80163-G. [DOI] [PubMed] [Google Scholar]
  • 43.Chen T, Wu Q, Zhang Y, Zhang D. NDUFV2 regulates neuronal migration in the developing cerebral cortex through modulation of the multipolar-bipolar transition. Brain Res. 2015;1625:102–110. doi: 10.1016/j.brainres.2015.08.028. [DOI] [PubMed] [Google Scholar]
  • 44.Washizuka S, Iwamoto K, Kazuno AA, Kakiuchi C, Mori K, Kametani M, Yamada K, Kunugi H, Tajima O, Akiyama T, et al. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder in Japanese and the National Institute of Mental Health pedigrees. Biol Psychiatry. 2004;56:483–489. doi: 10.1016/j.biopsych.2004.07.004. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.


Articles from Experimental and Therapeutic Medicine are provided here courtesy of Spandidos Publications

RESOURCES